Pfizer and BioNTech begin trials for potential COVID-19 vaccine BNT162

Many pharmaceutical firms are competing to produce a virus vaccine that has sparked a pandemic and sparked more than 215,000 deaths worldwide, causing at least three million people to die.

As many as 100 possible COVID-19 candidate vaccines are now being created by biotech and testing teams worldwide, and at least five of them are being tested in people in Phase 1 clinical trials.

Both Pfizer and BioNTech are preparing, initially in Europe and the United States, to jointly conduct clinical trials in multiple testing sites for COVID-19 vaccine candidates.

BioNTech claimed in the following statement that the dose of BNT162 will be increased in a trial involving around 200 participants between 18 and 55 years.The companies predict that millions of vaccine doses are likely to be supplied by the end of 2020, subject to the technological performance of the production plan and to the approval by the regulatory authorities.

While a safe and effective vaccine remains more than a year away, researchers race to repurpose proven medications and non-drug treatments and to check new experimental drugs already pursued in clinical trials.